Journal of Cancer Therapy
Vol.5 No.12(2014), Paper ID 50773, 10
pages
DOI:10.4236/jct.2014.512110
A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting
Debra A. Patt, Debra Rembert, Menaka Bhor, Debajyoti Bhowmik, Sumati A. Rao
Health Economics and Outcomes Research, McKesson Specialty Health, The Woodlands, TX, USA
Health Economics and Outcomes Research, McKesson Specialty Health, The Woodlands, TX, USA
Health Economics and Outcomes Research, McKesson Specialty Health, The Woodlands, TX, USA
Health Economics and Outcomes Research, McKesson Specialty Health, The Woodlands, TX, USA
Health Economics and Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ, USA
Copyright © 2014 Debra A. Patt, Debra Rembert, Menaka Bhor, Debajyoti Bhowmik, Sumati A. Rao et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Patt, D. , Rembert, D. , Bhor, M. , Bhowmik, D. and Rao, S. (2014) A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting.
Journal of Cancer Therapy,
5, 1049-1058. doi:
10.4236/jct.2014.512110.